Medscape: A Brave New World in Type 2 Diabetes Treatment and Beyond

Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke's Health System, joined Medscape InDiscussion to talk about the cardiovascular effects of type 2 diabetes medications.

"As a cardiologist who has been interested in this for so long, I'm looking at the most promising developments for new medications for treating cardiovascular disease, both atherosclerotic cardiovascular disease (ASCVD) and heart failure," Kosiborod said. "And the most promising developments are coming from the field of metabolism."

Listen to or read the Medscape InDiscussion episode: A Brave New World in Type 2 Diabetes Treatment and Beyond

Related Content

Mar. 1, 2022

Medwire News: Virtual CHIEF-HF Trial Supports Canagliflozin in Heart Failure
The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure (HF) symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.
Feb. 21, 2022

Scientific American: The Next 100 Years of Diabetes Care
On the anniversary of the discovery of insulin, experts reflect on how much progress has been made to treat and manage diabetes—and how much more is necessary.
Medscape logo
Dec. 23, 2021

Medscape: SGLT2 Inhibitors in Primary Care: 'All Hands on Deck' for Improving Heart Failure Outcomes
Mikhail Kosiborod, MD, explains why primary care is critical for the effective implementation of SGLT2 inhibitors in heart failure.